Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Heart Failure × nicotinamide-beta-riboside × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcopenia 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peripheral Nervous System Diseases 1 Neoplasms 1 Myelodysplastic Syndromes 1 Muscle Weakness 1 Leukemia, Myeloid 1 Heart Failure 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Cardiotoxicity 1 Breast Neoplasms 1 Anemia, Aplastic 1

Interventions

Echocardiography 4 Standard of Care 3 Exercise 3 Electrocardiography 3 sacubitril and valsartan sodium hydrate drug combination 2 Surveys and Questionnaires 2 Spironolactone 2 Rituximab 2 Nutrition Assessment 2 Lenalidomide 2 Ivabradine 2 Control Groups 2 Carvedilol 2 Blood Specimen Collection 2 Atorvastatin 2 Adrenergic beta-Antagonists 2 ziprasidone 1 pertuzumab 1 pegfilgrastim 1 obinutuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 acalabrutinib 1 Zolpidem 1 Watchful Waiting 1 Warfarin 1 Vincristine 1 Vecuronium Bromide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05732051 2023-03-17

NARNIA

University Hospital, Akershus

Phase 2 Recruiting

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡